Glenn Goddard
Director of Finance/CFO bei INTELLIA THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Derzeit bekleidet Glenn Goddard die Position des Executive VP, Chief Financial & Accounting Officer bei Intellia Therapeutics, Inc. Zuvor war er Senior Vice President-Finance bei Agios Pharmaceuticals, Inc. und Chief Financial Officer bei Generation Bio Co. sowie Controller bei ImmunoGen, Inc. und Vice President-Finance bei Archemix Corp. sowie Principal bei Ernst & Young LLP und Principal bei Feeley & Driscoll PC. Glenn Goddard erwarb einen Bachelor-Abschluss an der Bentley University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.03.2024 | 69 213 ( 0,07% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Glenn Goddard
| Unternehmen | Position | Beginn |
|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Director of Finance/CFO | 29.10.2018 |
AvenCell Therapeutics, Inc.
 AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Director/Board Member | - |
Ehemalige bekannte Positionen von Glenn Goddard
| Unternehmen | Position | Ende |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Director of Finance/CFO | 19.09.2016 |
| GENERATION BIO CO. | Director of Finance/CFO | - |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Comptroller/Controller/Auditor | - |
Ausbildung von Glenn Goddard
| Bentley University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| GENERATION BIO CO. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
AvenCell Therapeutics, Inc.
AvenCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AvenCell Therapeutics, Inc. is a biopharmaceutical company that develops immunotherapies to treat cancers. The private company is based in Cambridge, MA and has subsidiaries in Germany. Andrew D. Schiermeier has been the CEO of the company since 2021. | Health Technology |
